Phoenix Molecular Designs Announces First Patient Dosed in Phase 1b Clinical Trial of PMD-026 Taking Aim at Triple Negative Breast Cancer

Written by Guest User

Nov. 24
2020

SAN DIEGO and VANCOUVER, BC, Nov. 24, 2020 - PhoenixMD today announced that the first patient has been dosed in their Phase 1b clinical trial of PMD-026. This RSK targeting trial is a first of its kind in the battle to combat the most aggressive subtype of breast cancer, known as Triple Negative Breast Cancer (TNBC), which claims the lives of thousands of patients each year.

Read the story here

Guest User
Previous

World-Renowned Cancer Researcher, Dr. Alan Ashworth, Joins Phoenix Molecular Designs Advisory Board
Next

Phoenix Molecular Designs Initiates its Phase 1/1b Program to Evaluate PMD-026 in Patients with Resistant Forms of Advanced Breast Cancer